Below are the financial statements of Sino Biopharmaceutical, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in billions of CNY | 2024 | 2023 |
|---|---|---|
| Continuing operations revenue | 28.87a | 26.2a |
| Cost of sales | -5.34a | -4.99a |
| Gross profit | 23.53a | 21.21a |
| Other income | 1.21a | 0.76a |
| Other losses, net | -1.18a | -0.14a |
| Selling and distribution costs | -10.08a | -9.19a |
| Administrative expenses | -2.08a | -1.87a |
| Other expenses | -6.2a | -4.7a |
| Including: research and development costs | -5.09a | -4.4a |
| Finance income | 0.5a | 0.38a |
| Finance costs | -0.3a | -0.5a |
| Net finance income/(costs) | 0.2a | -0.12a |
| Share of profits and losses of associates and joint ventures | -0.12a | -0.53a |
| Profit before tax from continuing operations | 5.28a | 5.41a |
| Income tax expense | -0.49a | -0.8a |
| Profit for the year from continuing operations | 4.78a | 4.61a |
| Discontinued operations profit for the year from discontinued operations | 1.58a | 0.48a |
| Profit for the year | 6.36a | 5.1a |
| Attributable to: owners of the parent | 3.5a | 2.33a |
| Attributable to: non-controlling interests | 2.86a | 2.77a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.